Literature DB >> 32409121

Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR.

Yaoyao Lou1, Caixia Chen1, Xiaolu Long1, Jia Gu1, Min Xiao1, Di Wang1, Xiaoxi Zhou1, Tongjuan Li1, Zhenya Hong1, Chunrui Li1, Jianfeng Zhou1, Liting Chen2.   

Abstract

Chimeric antigen receptor (CAR) T-cell immunotherapy is a new strategy for the treatment of refractory B-cell malignancies; therefore, the rapid and accurate quantification of CAR transgene copy number is essential. Real-time PCR was used for quantifying the copy number of chimeric antigen receptor transgene. Droplet digital PCR (ddPCR) is an absolute quantification method that does not require a standard curve. In this study, key performance parameters of the ddPCR and real-time PCR methods were assessed, including linearity, detection range, the lower limit of detection, repeatability, reproducibility, and accuracy, using a series of gradient diluted standards and clinical peripheral blood samples from CAR T-cell patients. The two platforms showed a good correlation for the standards (Pearson R2 = 0.9966; P < 0.0001) and clinical samples (Pearson R2 = 0.8952; P < 0.0001), and both showed good linearity (R2 = 0.9996 for ddPCR; R2 = 0.9984 for real-time PCR) over the detection range. Compared with real-time PCR, ddPCR showed lower intra-assay and interassay CVs for the series of diluted standards, which indicated ddPCR has better repeatability and reproducibility. The limit of detection of ddPCR was lower compared with that of real-time PCR. The combined results suggest that ddPCR is a more promising tool for the detection and quantification of the chimeric antigen receptor transgene copy number.
Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32409121     DOI: 10.1016/j.jmoldx.2020.02.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  3 in total

1.  Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Authors:  Jia Wei; Min Xiao; Zekai Mao; Na Wang; Yang Cao; Yi Xiao; Fankai Meng; Weimin Sun; Ying Wang; Xingcheng Yang; Liting Chen; Yicheng Zhang; Haichuan Zhu; Shangkun Zhang; Tongcun Zhang; Jianfeng Zhou; Liang Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-11

2.  A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy.

Authors:  Wei Mu; Xiaolu Long; Haodong Cai; Caixia Chen; Guang Hu; Yaoyao Lou; Shugang Xing; Di Wang; Jue Wang; Min Xiao; Kun Wang; Zhongyi Sun; Chunrui Li; Jianfeng Zhou; Liting Chen
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

3.  Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment.

Authors:  Soragia Athina Gkazi; Emma Gravett; Carla Bautista; Jack Bartram; Sara Ghorashian; Stuart Paul Adams
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.